Richard Doll Seminar - SGLT2 inhibition for treating diabetes – an approach which achieves far more than just lowering glucose?

David Matthews is the Emeritus Founding Chairman of OCDEM and Professor of Diabetic Medicine at the University of Oxford, past NIHR Senior Investigator and Founding Director of the Oxford Health Alliance. He is currently Dean of Harris Manchester College, Oxford. He chaired the EASD/ADA group that produced the international guidelines on the treatment of type 2 diabetes – both in 2012 and in 2015.

His research interests include personalised medicine, the aetiopathology and treatment of type 2 diabetes, modelling of insulin resistance, the incretin axis and glucagon-like peptide-1, pulsatile insulin secretion, and the global obesity epidemic. He previously gave the Banting Memorial Lecture at Diabetes UK (‘Type 2 diabetes: the Black Death of the 21st century’). He has authored more than 300 academic peer-reviewed publications and sits on the editorial board of several professional journals.

Major trial results over the least 3 years have demonstrated the promise of SGLT2 inhibitor therapy for cardiovascular, cardiovascular and heart failure outcomes in diabetes. Professor Matthews is co-chair of the CANVAS and CANVAS-R trials of the SGLT2 inhibitor, canagliflozin, and he will discuss the CANVAS program, and its results in this seminar.